An observational study in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 6 sites in 4 countries. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Novo Nordisk A/S · Observational
Among 638 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 21 open to participants now, 25 under way, 7 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.
Among the 638 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 150th largest by planned enrollment of the 215 observational ones that give a count, is one of 19 that started in 2026, is one of 215 observational ones, reaches primary completion later than 4 of the 24 other live ones, and was the 626th registered.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →21 of the 638 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Novo Nordisk A/S · Sites in United States
Novo Nordisk A/S · Sites in United States
Novo Nordisk A/S · Sites in United States
Novo Nordisk A/S · Sites in United States, Argentina, Brazil and 13 more countries
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
638 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 19 started in 2026.
This study's planned enrollment of 400 is above the median of 300 across 1,741 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 205 across the 423 interventional studies, 938 across the 215 observational. Of the 602 that completed or were terminated, 174 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,404 studies on the registry; 101 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 100 (49%) have results posted.
8 of the studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05689372Novo Nordisk A/SRegulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | 2026-11-30 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Among the 638 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
Participants with T2DM identified in south asian countries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with T2DM identified in south asian countries.
Other: No treatment given
No treatment given
Cardiometabolic profile: Systolic blood pressure at baseline
Millimetres of mercury (mmHg).
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Waist circumference at baseline
Measured in centimetre (cm).
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Hip circumference at baseline
Measured in cm.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Height at baseline
Measured in cm.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Weight at baseline
Measured in kilogram (kg).
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Total cholesterol at baseline
Measured in millimoles per liter (mmol/L).
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: High-density lipoprotein cholesterol (HDL-C) at baseline
Measured in mmol/L.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Low-density lipoprotein cholesterol (LDL-C) at baseline
Measured in mmol/L.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Non High-density lipoprotein cholesterol (Non-HDL-C) at baseline
Measured in mmol/L.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Triglycerides at baseline
Measured in mmol/L.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Glycated haemoglobin (HbA1c) at baseline
Measured in mmol/L.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Fasting plasma glucose (FPG) at baseline
Measured in mmol/L.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: estimated glomerular filtration rate (eGFR) at baseline
Measured in mL/min/1.73m\^2.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Cardiometabolic profile: Serum creatinine at baseline
Measured in mL/min/1.73m\^2.
Time frame: At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date
Proportion of participants classified into CVD risk categories (very high, high, moderate or low risk) - Yes/No
Measured in percentage (%) of participants.
Time frame: At baseline: Status at the index date or, if unavailable, the closest record within the 12 months prior to the index date
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.